GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 2 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $77,800,000 | +124.7% | 1,142,444 | +5.4% | 0.01% | +140.0% |
Q2 2022 | $34,628,000 | -8.0% | 1,083,836 | -0.3% | 0.01% | 0.0% |
Q1 2022 | $37,640,000 | +19.7% | 1,086,624 | +1.2% | 0.01% | +25.0% |
Q4 2021 | $31,437,000 | +16.1% | 1,074,035 | +1.1% | 0.00% | 0.0% |
Q3 2021 | $27,075,000 | -29.9% | 1,062,605 | -3.7% | 0.00% | -20.0% |
Q2 2021 | $38,625,000 | +23.1% | 1,102,963 | +43.3% | 0.01% | 0.0% |
Q1 2021 | $31,366,000 | -3.7% | 769,723 | +2.4% | 0.01% | 0.0% |
Q4 2020 | $32,557,000 | -14.3% | 751,730 | +9.1% | 0.01% | -28.6% |
Q3 2020 | $37,989,000 | -16.0% | 688,965 | -3.8% | 0.01% | -30.0% |
Q2 2020 | $45,202,000 | +0.2% | 716,034 | -18.9% | 0.01% | -16.7% |
Q1 2020 | $45,102,000 | -65.5% | 882,803 | -46.3% | 0.01% | -14.3% |
Q4 2019 | $130,576,000 | +237.9% | 1,642,688 | +106.2% | 0.01% | +55.6% |
Q3 2019 | $38,649,000 | +0.3% | 796,569 | +8.7% | 0.01% | 0.0% |
Q2 2019 | $38,551,000 | +7.5% | 732,923 | +8.1% | 0.01% | 0.0% |
Q1 2019 | $35,870,000 | -29.5% | 677,697 | -45.3% | 0.01% | +12.5% |
Q4 2018 | $50,878,000 | +149.6% | 1,239,460 | +131.1% | 0.01% | +33.3% |
Q3 2018 | $20,382,000 | -10.9% | 536,383 | +6.0% | 0.01% | -14.3% |
Q2 2018 | $22,877,000 | +12.8% | 506,145 | +20.6% | 0.01% | 0.0% |
Q1 2018 | $20,275,000 | +51.1% | 419,787 | +23.1% | 0.01% | +40.0% |
Q4 2017 | $13,415,000 | +29.7% | 340,951 | +2.4% | 0.01% | +25.0% |
Q3 2017 | $10,342,000 | +31.6% | 333,076 | +15.9% | 0.00% | +33.3% |
Q2 2017 | $7,859,000 | -12.8% | 287,395 | +17.5% | 0.00% | -25.0% |
Q1 2017 | $9,015,000 | +307.4% | 244,667 | +59.7% | 0.00% | +300.0% |
Q4 2016 | $2,213,000 | -28.6% | 153,169 | +13.9% | 0.00% | -50.0% |
Q3 2016 | $3,099,000 | +198.0% | 134,467 | +114.4% | 0.00% | +100.0% |
Q2 2016 | $1,040,000 | +22.8% | 62,715 | +17.4% | 0.00% | – |
Q1 2016 | $847,000 | -49.7% | 53,433 | +2.6% | 0.00% | -100.0% |
Q4 2015 | $1,684,000 | -3.4% | 52,099 | +26.0% | 0.00% | 0.0% |
Q3 2015 | $1,743,000 | – | 41,351 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |